| Characteristic | Net income/loss in million U.S. dollars |
|---|---|
| Q2 '22 | -270.01 |
| Q1 '22 | 513.29 |
| Q4 '21 | 181.69 |
| Q3 '21 | 536.76 |
| Q2 '21 | 65.65 |
| Q1 '21 | 68.01 |
| Q4 '20 | 222.12 |
| Q3 '20 | 28.66 |
| Q2 '20 | -1,228.01 |
| Q1 '20 | -8.4 |
| Q4 '19 | 118.77 |
| Q3 '19 | 36.52 |
| Q2 '19¹ | 1,119.56 |
| Q1 '19 | 190.8 |
| Q4 '18 | 255.3 |
| Q3 '18 | 789.18 |
| Q2 '18 | 100.12 |
| Q1 '18 | 61 |
| Q4 '17 | 91.08 |
| Q3 '17 | -21.1 |
| Q2 '17 | -116.49 |
| Q1 '17 | -61.56 |
| Q4 '16 | -167.05 |
| Q3 '16 | -102.87 |
| Q2 '16 | -107.22 |
| Q1 '16 | -79.73 |
| Q4 '15 | -90.24 |
| Q3 '15 | -131.69 |
| Q2 '15 | -136.66 |
| Q1 '15 | -162.44 |
| Q4 '14 | -125.35 |
| Q3 '14 | -175.46 |
| Q2 '14 | -144.64 |
| Q1 '14 | -132.36 |
| Q4 '13 | -511.47 |
| Q3 '13 | -64.6 |
| Q2 '13 | -42.23 |
| Q1 '13 | -27.03 |
| Q4 '12 | -8.71 |
| Q3 '12 | -21.59 |
| Q2 '12 | -27.58 |
| Q1 '12 | -21.52 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
July 2022
Worldwide
Q1 2011 to Q2 2022
¹As per the Q2 2019 shareholder letter: "Our net benefit from income taxes in Q2 was more than $1 billion, largely driven by a significant tax benefit related to the establishment of a deferred tax asset for corporate structuring for certain geographies. Excluding the tax benefit, our provision for income taxes was $51 million."
² As per the Q2 2020 shareholder letter: "In Q2 2020, we recognized a deferred tax asset valuation allowance of $1.1 billion and a non-cash income tax expense based primarily on cumulative taxable losses driven primarily by COVID-19. This valuation allowance would be reversed in the event, and to the extent, that it is more likely than not that there will be sufficient taxable income to realize the tax benefit. Depending on the extent and severity of COVID-19’s impact, we could have an additional valuation allowance against deferred tax assets in a future period. As a result of the valuation allowance, we incurred a net loss of $1.2 billion in Q2"
